UAE Law and Practice Contributed by: Haykel Hajjaji, Julie Teperow, Robin Blaney and Winsome Cheung, Covington & Burling LLP
Covington & Burling LLP offers one of the world’s largest and most comprehensive life sciences-fo- cused practices. Its clients – spanning every sec- tor and ranging from emerging biotech ventures to global pharmaceutical companies and major trade associations – trust the firm with their most complex business challenges. The firm has clients across the entire product life cycle, going well beyond tradition- al legal services to enable efficient R&D, successful launch and commercialisation, and long-term value maximisation. Covington supports numerous leading life sciences companies on strategic transactions,
M&A, financings, and emerging issues including digi- tal health, post‑Brexit regulatory divergence, privacy, innovation incentives, reimbursement, and evolving medical device and diagnostic regulations. It also guides clients through rapidly shifting political and policy landscapes, including drug‑pricing initiatives and implications for compliance, trade, antitrust, and litigation. The team includes more than a hundred dedicated life sciences lawyers, many of whom pre- viously held senior positions at regulatory agencies, major manufacturers, or industry associations.
Authors
Haykel Hajjaji is a partner at Covington & Burling LLP who advises global corporations, sovereign investors, and financial institutions on complex cross-border transactions, regulatory strategy, and market entry
emerging markets. In addition, she handles regulatory aspects of corporate and commercial transactions.
Robin Blaney is a partner at Covington & Burling LLP who advises pharmaceutical, biotechnology, and medical device companies on a broad range of regulatory, compliance, transactional, and legislative matters,
across the Middle East. His practice spans corporate, M&A, and commercial advisory matters, with a focus on strategic expansion into the Gulf. Haykel has deep expertise at the intersection of innovation, regulation, and geopolitics, particularly across AI, data centres, life sciences, defence, supply chain, and infrastructure. With over two decades of experience, he counsels clients on market entry, transaction structuring, foreign investment regimes, and legal risk in sensitive environments.
as well as commercial agreements spanning the full product life cycle. He regularly supports human and veterinary pharmaceutical companies on advertising and GxP issues, including clinical trials, pharmacovigilance, and manufacturing. Robin also advises on the regulatory aspects of M&A, licensing, and collaborative transactions, with significant experience in transitional regulatory, and supply arrangements. His commercial expertise includes clinical trial, manufacturing, and distribution agreements, and he has notable experience structuring international distribution and licensing frameworks.
Julie Teperow is a special counsel at Covington & Burling LLP who advises multinational clients on complex local and international regulatory, public policy, and corporate matters across sectors including life sciences,
technology, and consumer products. She has extensive experience in regional cross-border compliance, supporting clients as they navigate regulatory frameworks and the practical challenges of doing business in the Middle East and North Africa. Julie also advises on government affairs in the GCC, focusing on commercial, trade, and market access issues, and supports clients entering
Winsome Cheung is a partner at Covington & Burling LLP who
represents global pharmaceutical and biotechnology companies on strategic partnering and collaboration arrangements. A former scientist with a PhD in medicine, she draws on deep scientific and industry insight to advise clients across the life
365 CHAMBERS.COM
Powered by FlippingBook